According to the announcement from Zhitong Finance and Economics APP, shandong lukang pharmaceutical (600789.SH) recently received the "Pharmaceutical Registration Certificate" for apixaban (Certificate Number: 2024S02715) and the "Chemical Raw Materials Market Application Approval Notice" for apixaban active pharmaceutical ingredient (Notice Number: 2024YS01205).

Apixaban is a highly effective, orally active, reversible, direct, and highly selective Xa indicator active site inhibitor, whose anti-thrombotic activity does not depend on antithrombin III. Apixaban inhibits the activation of Xa indicators by occupying their active sites, resulting in an anti-coagulant effect. Apixaban can even inhibit Xa indicators bound to thrombi, with good therapeutic effects, high selectivity, and low bleeding risk. The drug is suitable for adult patients undergoing elective hip or knee replacement surgeries to prevent Venous Thromboembolism (VTE).